Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNPR Monopar Therapeutics

Trading 09-10 10:56:37 EDT

111.09

-1.29

-1.15%

High112.56	Low108.84	Vol24.64K
Open110.55	D1 Closing112.38	Amplitude3.31%
Mkt Cap742.37M	Tradable Cap497.44M	Total Shares6.68M
T/O2.73M	T/O Rate0.55%	Tradable Shares4.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNPR","market":"US","secType":"STK","nameCN":"Monopar Therapeutics","latestPrice":111.09,"timestamp":1789052193516,"preClose":112.38,"halted":0,"volume":24639,"delay":0,"changeRate":-0.011478910838227373,"floatShares":4477800,"shares":6682584,"eps":-2.180383,"marketStatus":"Trading","change":-1.29,"latestTime":"09-10 10:56:37 EDT","open":110.55,"high":112.56,"low":108.84,"amount":2733554.488746,"amplitude":0.033102,"askPrice":111,"askSize":60,"bidPrice":110.27,"bidSize":68,"shortable":3,"etf":0,"ttmEps":-2.180383,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1576731600000,"exchange":"NASDAQ","adjPreClose":112.38,"preHourTrading":{"tag":"盘前","latestPrice":111.6,"preClose":112.38,"latestTime":"09:28 EDT","volume":34,"amount":3796.83032,"timestamp":1789046880058,"change":-0.78,"changeRate":-0.006941,"amplitude":0.030166},"postHourTrading":{"tag":"盘后","latestPrice":112,"preClose":112.38,"latestTime":"19:30 EDT","volume":3567,"amount":399965.58,"timestamp":1788996607185,"change":-0.38,"changeRate":-0.003381,"amplitude":0.003559},"volumeRatio":0.778443},"requestUrl":"/m/hq/s/MNPR/","defaultTab":"news","newsList":[{"id":"2662039325","title":"Monopar Therapeutics Director Raymond Anderson Sells USD 349,125 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039325","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662039325?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:28","pubTimestamp":1787869711,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common sharesDirector Raymond Anderson sold 3,142 Monopar Therapeutics common shares on Aug. 25, 2026 at prices around USD 110.04 to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8jpWGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monopar Therapeutics Director Raymond Anderson Sells USD 349,125 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660742856","title":"Monopar Names Jeffrey D. Kent Executive Vice President, Head of Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2660742856","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660742856?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:03","pubTimestamp":1787141025,"startTime":"0","endTime":"0","summary":"Monopar names Jeffrey D. Kent executive vice president, head of medical affairsMonopar named Jeffrey D. Kent as executive vice president, head of medical affairs, effective Sept. 1, 2026.Role centers ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL7gLTvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288034","title":"Monopar Appoints Jeffrey D. Kent, M.d., as Executive Vice President, Head of Medical Affairs; Announces Two Alxn1840 Presentations at Aasld – the Liver Meeting® 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288034","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660288034?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:00","pubTimestamp":1787140803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA69GYB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660800144","title":"Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660800144","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660800144?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:57","pubTimestamp":1786971477,"startTime":"0","endTime":"0","summary":"In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00. S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614261","title":"Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614261","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659614261?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:27","pubTimestamp":1786645641,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics  shares were down 4.2% in afternoon trading on Thursday after Cantor Fitzgerald downgraded the company's stock to neutral from overweight and adjusted the price target to $119 from $109.Trading volume stood at more than 115,000 shares against a daily average of around 222,000.Price: 110.13, Change: -4.78, Percent Change: -4.16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659633831","title":"Monopar Therapeutics is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2659633831","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659633831?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:31","pubTimestamp":1786631460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659560621","title":"Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109","url":"https://stock-news.laohu8.com/highlight/detail?id=2659560621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659560621?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:17","pubTimestamp":1786619852,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) has an average rating of buy and mean price target of $125.58, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659132067","title":"Barclays Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659132067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659132067?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:25","pubTimestamp":1786609542,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $128.00. Darout covers the Health...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659943180","title":"Monopar Therapeutics Inc. : Leerink Partners Raises Target Price to $145 from $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2659943180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659943180?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:00","pubTimestamp":1786593655,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN4491O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659018860","title":"Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659018860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659018860?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:30","pubTimestamp":1786566610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monopar Therapeutics Inc (MNPR) and AbSci (ABSI) wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-monopar-therapeutics-inc-mnpr-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-monopar-therapeutics-inc-mnpr-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","BK4539","BK4139","ARKG","BK4121","ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915903","title":"Monopar Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915903","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915903?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:10","pubTimestamp":1786543844,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings SummaryMonopar Therapeutics Inc.MNPR.OQreported a quarterly adjusted loss of 62 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990873","title":"Monopar Therapeutics' Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990873?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:47","pubTimestamp":1786542423,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics  reported a Q2 net loss Wednesday of $0.62 per diluted share, compared with a loss of $0.35 a year earlier.Analysts surveyed by FactSet expected a loss of $0.66.The company did not report any revenue for the quarter.As of June 30, the company said it has $134.3 million in cash, cash equivalent and investments. It added that it expects its current funds to support operations through at least Dec. 31, 2027.Price: 115.00, Change: +0.54, Percent Change: +0.47","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658668908","title":"Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658668908","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658668908?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:32","pubTimestamp":1786541569,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses of $(0.35) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61141793/monopar-therapeutics-q2-eps-0-62-misses-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908324","title":"Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908324?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:30","pubTimestamp":1786541400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2QV4ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657406016","title":"Monopar Therapeutics Inc. Expected to Post a Loss of 62 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657406016","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657406016?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:30","pubTimestamp":1786120208,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. <MNPR.OQ> expected to post a loss of62cents a share - Earnings PreviewMonopar Therapeutics Inc.MNPR.OQMNPR.Ois expected to  show no change in quarterly revenue when it report","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N44424E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653830980","title":"BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup","url":"https://stock-news.laohu8.com/highlight/detail?id=2653830980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653830980?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:45","pubTimestamp":1784886322,"startTime":"0","endTime":"0","summary":"Analyst Jeet Mukherjee of BTIG maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $117.00. Jeet Mukherjee has given his Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/btigs-mukherjee-initiates-buy-on-monopar-therapeutics-citing-emerging-head-neck-cancer-data-and-favorable-riskreward-setup-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/btigs-mukherjee-initiates-buy-on-monopar-therapeutics-citing-emerging-head-neck-cancer-data-and-favorable-riskreward-setup-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653712379","title":"U.S. Research Roundup-alphabet, IBM, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2653712379","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653712379?lang=en_us&edition=fundamental","pubTime":"2026-07-23 15:25","pubTimestamp":1784791555,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alphabet, IBM, TeslaJuly 23 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alphabet, IBM and Tesla,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL4N43P0K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWBC","T","CVX","BLFS","ARWR","CDNA","DTRE","FTNT","MCB","CCI","GSHD","CASH","GOOX","IBM","ROL","BP","KDP","FTAI","RCTR","RJF","GOOGL","CVNA","CELH","BYRE","GILD","IBB","MPC","NTRS","QQQA","XOM","KNX","AMD","GEV","IPAR","SNDK","FAI","PEGA","SEIC","CME","PSX","TMED","SF","BMI","IEO","FOWF","MNPR","EOG","EFX","NOC","XDAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653617657","title":"Monopar Therapeutics is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2653617657","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653617657?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:09","pubTimestamp":1784736540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 12:09 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653376963","title":"Monopar Therapeutics Inc. : H.c. Wainwright Raises Target Price to $125 from $105","url":"https://stock-news.laohu8.com/highlight/detail?id=2653376963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653376963?lang=en_us&edition=fundamental","pubTime":"2026-07-22 23:05","pubTimestamp":1784732735,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nAZN4T9BVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653757444","title":"Monopar Starts Rolling FDA NDA Submission for Alxn1840 in Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757444","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757444?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:01","pubTimestamp":1784721669,"startTime":"0","endTime":"0","summary":"Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson diseaseMonopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 in Wilson disease.The FDA authorized the rolling","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL2pY6Hf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","BK4588","MNPR","SG9999014039.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","BCDF","NDAQ","IE00BN0W2T93.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monopartx.com","stockEarnings":[{"period":"1week","weight":-0.0335},{"period":"1month","weight":-0.0341},{"period":"3month","weight":0.9017},{"period":"6month","weight":0.8618},{"period":"1year","weight":1.5012},{"period":"ytd","weight":0.721}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.22612},{"month":2,"riseRate":0.285714,"avgChangeRate":0.090755},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.182533},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.03289},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.037743},{"month":6,"riseRate":0.714286,"avgChangeRate":0.099323},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.016558},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.131595},{"month":9,"riseRate":0.428571,"avgChangeRate":0.41557},{"month":10,"riseRate":0.5,"avgChangeRate":0.223985},{"month":11,"riseRate":0.666667,"avgChangeRate":0.047001},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.031256}],"exchange":"NASDAQ","name":"Monopar Therapeutics","nameEN":"Monopar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monopar Therapeutics,MNPR,Monopar Therapeutics股票,Monopar Therapeutics股票老虎,Monopar Therapeutics股票老虎国际,Monopar Therapeutics行情,Monopar Therapeutics股票行情,Monopar Therapeutics股价,Monopar Therapeutics股市,Monopar Therapeutics股票价格,Monopar Therapeutics股票交易,Monopar Therapeutics股票购买,Monopar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction